Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts Eye and Ear Infirmary
Study ID
NCT04057053
Phase
EARLY_PHASE1
Status
Completed

Conditions

  • Cataract
  • Fuchs' Endothelial Dystrophy

Eligibility Criteria

Sex
ALL
Age
50 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil 0.02% Ophthalmic Solution — DRUG
    Use of Netarsudil 0.02% ophthalmic solution daily after surgery

Study Details

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

Key Dates

Start date
Oct 2, 2018
Status verified
Jan 2021
Primary completion
Dec 20, 2020
Completion
Dec 20, 2020

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Netarsudil use
    Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
  • Active Comparator: Standard of care + possible rescue drop
    Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented

Primary Outcome Measure

Time to corneal clearance [ Time Frame: Through study completion, an average of 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts Eye and Ear InfirmaryBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Massachusetts Eye and Ear Infirmary· Boston, MA

Related Studies